Introduction: Diabetes mellitus (DM) is a group of common metabolic disorders that is characterized by hyperglycemia. It is reported that most patients with Type 2 diabetes could have dyslipidemia at varying degrees, characterized by the increased levels of triglycerides (TGs) and low-density lipoprotein-cholesterol (LDL-C) and decreased high-density lipoprotein-cholesterol (HDL-C). The non-HDL-C was introduced to refine the risk estimation beyond LDL-C in the presence of elevated TGs levels ≥200 mg/dl, and it also estimates the level of all Apo-B-carrying lipoproteins. This study was conducted to correlate the glycated hemoglobin with non-HDL-C and lipid profile in Type 2 DM and non-DM patients. Materials and Methods: The present case and control study was conducted on 204 participants who attended the Medical Outpatient Department at KLE's Hospital, Belagavi, Karnataka, India. 102 Type 2 diabetic patients and 102 age-and gender-matched healthy controls were evaluated for serum fasting blood sugar (FBS), blood HbA1c, serum fasting lipid profile, and non-HDL-C. Data were analyzed using the SPSS software version. 20. Results: The results of our study showed that the mean ± standard deviation levels of FBS were 157.18 ± 41.8 and HbA1c was 8.19 ± 1.68, which were significantly increased in Type 2 diabetes patients as compared to controls with FBS 99.96 ± 12.94 and HbA1C 5.56 ± 0.40 with P < 0.05. The levels of total cholesterol, LDL-C, and TGs significantly increased in cases as compared to controls with P < 0.05. Whereas, non-HDL-C levels significantly increased in cases 147.75 ± 30.42 as compared to controls 111.26 ± 31.9 with P < 0.05. Conclusion: The result of this study showed that HbA1c was associated with a significant increase in non-HDL levels in cases as compared to controls. Thus, non-HDL-C preferred as one of the markers for diabetic dyslipidemia and cardiovascular risk marker than LDL alone.
Introduction
Diabetes mellitus (DM) is a group of common metabolic disorders that are characterized by hyperglycemia. [1] It is a heterogeneous group of multifactorial, polygenic syndromes characterized by increased fasting glucose caused by a relative or absolute deficiency in insulin, which leads to an increased concentration of glucose in the blood. [2] According to the WHO, 422 million adults were suffering from diabetes in 2014 as compared to 108 million in 1980. [3] In India, DM is not an epidemic but has turned into a pandemic, and thus, India is also known as the diabetic capital of the world.
In the year 2017, 72.9 million Indians were suffering from diabetes. Because of diabetes, 1.5 million people died in 2012, and in addition, 2.2 million deaths occurred This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
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due to an increased risk of coronary artery disease and other diseases. [3] It is reported that most patients with Type 2 diabetes could have dyslipidemia at varying degrees, characterized by the increased levels of triglycerides (TGs) and low-density lipoprotein-cholesterol (LDL-C) and decreased high-density lipoprotein-cholesterol (HDL-C). It is also shown that there is a significant high level of hypercholesterolemia and hyperlipidemia in Type 2 diabetic patients with cardiovascular disease (CVD) as compared to diabetic patients without CVD, which may increase the rate of mortality of these patients. More recently, the data showed that the lipid ratio is more sensitive in reflecting the morbidity and severity of coronary heart disease than individual lipid. However, some studies have shown that there is little relationship between HbA1c and lipid profile levels in Type 2 DM (T2DM) patients. [4] Access this article online Website: www.jscisociety.com DOI: 10.4103/jss.JSS_12_19
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The non-HDL-C was introduced to refine risk estimation beyond LDL-C in the presence of elevated TGs levels ≥200 mg/dl, and it also estimates the level of all apoB-carrying lipoproteins. Thus, non-HDL-C may represent a simple and affordable surrogate to apoB measurement, especially in patients with hypertriglyceridemic and diabetic patients. [5] The concentration of non-HDL-C is calculated by subtracting HDL-C from total cholesterol. It is a better marker of CVD than LDL because the levels of non-HDL can be measured from nonfasting samples, as opposed to LDL-C, and it is nonexpensive, which measures LDL particle number and total Apo-B concentration. [5] The National Cholesterol Education Program and Adult Treatment Panel (ATP) III have recommended the use of non-HDL-C in assessing CVD risk in patients with diabetes. Adult Treatment Panel ATP-III recommended a therapeutic goal for non-HDL-C is <100 mg/dl for the management of diabetic dyslipidemia in patients without acute coronary syndrome (ACS) and is <100 in patient who has ACS. [6, 7] Hence, non-HDL-C is a better marker of hyperlipidemia than LDL-C. This study was conducted to correlate the glycated hemoglobin with non-HDL-C and lipid profiles in T2DM and non-DM patients. The use of non-HDL-C and HbA1c would aid as a marker of diabetic dyslipidemia and cardiovascular risk marker than LDL alone. [7] 
Materials and Methods
The present case and control study was conducted in KLE Society's Dr. Prabhakar Kore Charitable Hospital, Belagavi, India, from January 2018 to December 2018. One hundred and two T2DM patients of both the gender and 102 age-and gender-matched healthy controls aged between 30 and 70 years, who attended the medicine outpatient department were studied. The present study includes a newly diagnosed T2DM or a known case of T2DM with or without treatment on oral hypoglycemic drugs or insulin and hypolipidemic drugs and age-and gender-matched healthy controls, whereas the study excludes Type 1 DM, females on oral contraceptive pills, anemia, nephrotic syndrome, chronic renal failure, cirrhosis or other liver diseases, pregnancy, thyroid disorders, and hemoglobinopathy. The diagnosis of Type 2 diabetes was established with the levels of HbA1c ≥6.5 and levels of fasting blood sugar (FBS) is ≥126 as per the ADA guideline. [8] The estimation of FBS and serum fasting lipid profile was done by hexokinase [9] [10] [11] and other enzymatic methods, respectively, [12] [13] [14] [15] using Roche/Hitachi COBAS fully automated analyzer and estimation of HbA1C using Bio-Rad D-10 HbA1c program.
Statistical analysis was performed using the SPSS software, version 20.0 for windows; IBM Corporation, Software Group, Route 100, Somers, New York 10589; continuous variables were expressed as mean ± standard deviation (SD) and qualitative data were expressed in percentages. An independent t-test was used to compare the parameters in case and control population. P < 0.05 was considered statistically significant.
Results
In this study, a total of 204 patients were evaluated. The overall distribution of patients is shown in Table 1 . Table 2 shows the comparison of levels of serum FBS, blood HbA1c, serum fasting lipid profile, (total cholesterol, LDL-C, HDL-C, and triglyceride), and non-HDL-C among the Type 2 diabetic patients and controls in the study population. The mean ± SD levels of FBS were 157.18 ± 41.8 and HbA1c was 8.19 ± 1.68, which were significantly increased in Type 2 diabetes patients as compared to controls with FBS 99.96 ± 12.94 and HbA1C 5.56 ± 0.40 with P < 0.05. The levels of total cholesterol, LDL-C, and TGs were significantly increased in cases as compared to controls with P < 0.05. Whereas, no significant difference was observed in the levels of HDL-C in cases as compared to controls. Whereas, non-HDL-C levels were significantly increased in cases 147.75 ± 30.42 as compared to controls 111.26 ± 31.9 with P < 0.05.
Discussion
The present study was conducted on 102 Type 2 diabetic cases who were clinically diagnosed according to the ADA guidelines and were aged between 30 and 70 years, of which 58 cases were male and 44 cases were female; the findings were compared with 102 apparently healthy age-and sex-matched controls. In this study, FBS, HbA1c, lipid profile, and non-HDL-C were investigated. Diabetic patients are at a higher risk of developing dyslipidemia and have greatly increased CVD risk as compared to nondiabetic individuals. [4] This study reveals a high prevalence of hypercholesterolemia, hypertriglyceridemia, high levels of LDL-C, and increased levels of non-HDL-C and low HDL-C levels, which are well-known risk factors for CVDs.
Insulin has an antilipolytic effect on adipose tissue. It inhibits hormone-sensitive lipase due to which it promotes the storage of triacylglycerol in adipocytes and decreases the secretion of circulating nonesterified fatty acids (NEFAs) from adipose tissue. [16] Circulating NEFAs are the substrate for very LDL-C, and hence, the production of VLDL-C is also reduced in hepatocytes. [17] Diabetic dyslipidemia mainly shows increased triacylglycerol and reduced HDL-C. Lipid abnormalities seen in patients with Type 2 diabetes are due to the insulin-resistant metabolic syndrome which shows the accumulation of triacylglycerol-rich lipoprotein and small-dense LDL particles with reduced HDL-C in plasma. This shows the role of insulin resistance in the pathophysiology of diabetic dyslipidemia. [16] In this study, the comparison of levels of FBS, HbA1c, lipid profile, and non-HDL-C among the Type 2 diabetic patients and controls in the study population was observed. The levels of FBS, HbA1c, total cholesterol, LDL-C, and TGs significantly increased in Type 2 diabetic cases as compared to controls. Whereas, non-HDL-C levels significantly increased in cases as compared to controls; the findings were similar to other studies conducted. [18, 19] The patient needs 9-12 h of fasting for measuring LDL-C, which may cause risk of hypoglycemia in a diabetic patient, whereas non-HDL-C calculated from the random serum sample, and it is a simple, convenient, cost-effective, and most importantly, it is a valid surrogate marker of Apo B in diabetic patients. Thus, non-HDL-C can be of great value in determining dyslipidemia in diabetic participants.
Conclusion
In this study, a total of 204 participants were evaluated. The result of this study showed that HbA1c was associated with a significant increase in non-HDL levels in cases as compared to controls. As non-HDL-C includes not only LDL-C but also cholesterol contained in all other atherogenic lipoproteins. Thus, non-HDL-C preferred as one of the markers for diabetic dyslipidemia and cardiovascular risk marker than LDL alone.
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